Results 71 – 80 of 250 for Enhertu (0.10 seconds)

Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint

Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint

Datopotamab deruxtecan and Enhertu show promising early clinical activity in patients with advanced non-small cell lung cancer

Datopotamab deruxtecan and Enhertu show promising early clinical activity in patients with advanced non-small cell lung cancer

AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19

AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19

AstraZeneca demonstrates growing leadership in breast cancer at SABCS with data from its innovative medicines and robust pipeline

New data from the DESTINY-Breast01 Phase II trial reinforce the efficacy of Enhertu in HER2-positive metastatic breast cancer New data from the ...

AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022

Enhertu data will show the potential to improve survival for metastatic breast cancer patients and define a new segment of HER2-low disease Results ...

AstraZeneca advances the science of cancer medicine with practice-changing data at the ASCO20 Virtual Scientific Program

data will highlight the transformative potential of Enhertu across multiple HER2-driven tumours and new data for Imfinzi plus tremelimumab in liver ...

AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023

early-stage resectable EGFR-mutated lung cancer Enhertu will show potential across a broad range of advanced HER2-expressing advanced cancers ...

AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022

Results will further underscore efficacy and safety of Imfinzi, Tagrisso and Lynparza across multiple cancers with high unmet need  Enhertu data ...

Full-year and Q4 2019 results

patients, most recently including regulatory approvals of Enhertu in breast cancer and Calquence in leukaemia. Our collaborations also progressed at ...

H1 2022 results

practice-changing data for several medicines including Enhertu in breast cancer, Farxiga in heart failure and Ultomiris in neuromyelitis optica ...

Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next